Real-World Use of Rituximab in the Treatment of Cold Agglutinin Disease in the United States: A Retrospective Study.

ABSTRACT:

Introduction

Rituximab is used off-label for treating cold agglutinin disease (CAD) in the United States; however, real-world data on its use are limited.

Methods

This study examined (1) treatment patterns, (2) prespecified safety outcomes, and (3) changes in hemolytic markers post rituximab infusion (threshold change from baseline: hemoglobin [Hb]: ≥2 g/dL increase; bilirubin or lactate dehydrogenase [LDH]: ≥50% decrease). Of 611 patients with CAD (Cohort 1) identified using Optum's de-identified Market Clarity database (2007-2021), 94 who received rituximab (Cohort 2) were included.

Results

Rituximab was predominantly used as monotherapy; the median (interquartile range; IQR) number of rituximab courses per patient was 1.0 (1.0-2.0); 24 (25.5%) patients had ≥1 incom

SUBMITTER: Piatek C 

PROVIDER: S-EPMC12255320 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature